Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)

Παρόμοια τεκμήρια

• Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
  ανά: Andtbacka, Robert H. I., κ.ά.
  Έκδοση: (2016)
• Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial
  ανά: Kaufman, Howard L, κ.ά.
  Έκδοση: (2014)
• Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma
  ανά: Johnson, Douglas B, κ.ά.
  Έκδοση: (2015)
• Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
  ανά: Andtbacka, Robert H. I., κ.ά.
  Έκδοση: (2016)
• Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
  ανά: Puzanov, Igor, κ.ά.
  Έκδοση: (2016)